JLE

Hématologie

MENU

Anti-angiogenic properties of imatinib mesylate Volume 10, issue 6, Novembre-Décembre 2004

Figures

See all figures

Authors
Service d’hématologie, hôpital Archet 1, 151 route S t Antoine de Ginestière, 06200 Nice, UMR 6543 CNRS-UNSA « Signalisation, biologie du développement et cancer », centre Antoine Lacassagne, 33 avenue Valombrose, 06000 Nice

Increased angiogenesis in bone marrow is one of the characteristics of chronic myeloid leukemia (CML). CML is a clonal myeloproliferative disorder of pluripotent hematopoietic stem cells with a specific cytogenetic abnormality, a balanced translocation between chromosomes 9 and 22. This translocation results in a Bcr/Abl chimeric gene that expresses an abnormal fusion protein showing constitutive tyrosine kinase activity. This protein induces cell disorders including Vascular Endothelial Growth Factor (VEGF) expression, one of the most potent angiogenic factor. We recently investigated the capacity of imatinib mesylate, a specific inhibitor of Bcr/Abl tyrosine kinase activity, to modulate VEGF expression. Thus, we shown that imatinib mesylate had anti-angiogenic properties. In this review, we will consider the several potential target of imatinib mesylate on angiogenesis and we will point out the interest of an anti-angiogenic strategy on the evolution of CML.